Key result
Combining one SES and one BMS is linked to favorable 6-month outcomes versus two SESs.
Why the study?
Does the combination of one BMS and one SES maintain safety and clinical outcomes compared to exclusive use of two SESs in patients with two-vessel CAD?
Observational
Does the combination of one BMS and one SES maintain safety and clinical outcomes compared to exclusive use of two SESs in patients with two-vessel CAD?
The combination of one sirolimus-eluting stent and one bare metal stent is a safe and feasible alternative to using two sirolimus-eluting stents in patients with two-vessel coronary artery disease.
Supports selective hybrid stenting in two-vessel CAD; hypothesis-generating and requires randomized confirmation.
Sirolimus-eluting stents (SESs; Cypher) have demonstrated a significant reduction in restenosis rates when compared to bare metal stents (BMSs). The purpose of this study was to evaluate the strategy of exclusive use of two SESs versus the combination of one BMS and one SES for two-vessel coronary artery disease (CAD). It was found that the selective use of one SES combined with one BMS in patients undergoing percutaneous coronary intervention that requires more than one stent is safe, feasible, and associated with favorable procedural, 30-day, and 6-month clinical outcomes when compared to the exclusive use of SESs.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2005) conducted an observational in Two-vessel coronary artery disease (CAD). Selective use of one sirolimus-eluting stent (SES) and one bare metal stent (BMS) vs. Exclusive use of two SESs was evaluated on Procedural, 30-day, and 6-month clinical outcomes. Selective use of one sirolimus-eluting stent combined with one bare metal stent was safe and associated with favorable 6-month clinical outcomes compared to exclusive use of two SESs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: